Blue Water Life Science Advisors, LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 9, 2024), Blue Water Life Science Advisors, LP reported 8 stock positions worth $102.8 million. Its top holding was Natera (NTRA) at 53.0% of the portfolio, followed by Guardant Health (GH, 16.0%) and Akoya Biosciences (AKYA, 10.7%). Compared with Q1 2024, it opened 1 new position, sold out of 1, added to 1 and reduced 1. The biggest buy was a new position in Caredx (CDNA) and the biggest sale an exit from Adaptive Biotechnologies (ADPT).
- Most Recent 13F
- Q2 2026
- Location
- LARKSPUR, CA
- CIK
- 0001789778
- Portfolio Value
- $102.8M (Q2 2024)
- SEC Filing
- 0001172661-24-003184 ↗ filed Aug 9, 2024
Holdings Value
Holdings 8 stocks · $102.8M
| NTRA Natera Inc. | 52.98% | 503,094 | $54.5M | No change |
| GH Guardant Health Inc. | 16.04% | 571,047 | $16.5M | No change |
| AKYA Akoya Biosciences Inc. | 10.69% | 4,697,785 | $11.0M | No change |
| CDNA Caredx Inc. | 7.70% | 510,000 | $7.9M | New |
| TXG 10X Genomics Inc. Class A | 4.35% | 230,000 | $4.5M | Add +18.3% |
| QTRX Quanterix Corp. | 3.58% | 278,393 | $3.7M | Reduce -9.9% |
| EXAS Exact Sciences Corp. | 2.36% | 57,343 | $2.4M | No change |
| MXCT Maxcyte Inc. | 2.30% | 603,937 | $2.4M | No change |
Portfolio Sells Q1 2024 → Q2 2024
Portfolio Buys Q1 2024 → Q2 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $158.8M | CDNA, TXG, PSNL, ADPT, GH |
| Q1 2026 | 10 | $124.7M | TXG, GH, CDNA, ADPT, TWST |
| Q4 2025 | 9 | $159.3M | GH, NTRA, ADPT, PSNL, QTRX |
| Q3 2025 | 7 | $109.6M | ADPT, GH, NTRA, PSNL, CDNA |
| Q2 2025 | 8 | $126.3M | NTRA, ADPT, GH, CDNA, TXG |
| Q1 2025 | 7 | $100.9M | GH, NTRA, ADPT, CDNA, AKYA |
| Q4 2024 | 9 | $112.9M | NTRA, GH, CDNA, ADPT, AKYA |
| Q3 2024 | 8 | $113.7M | NTRA, CDNA, EXAS, AKYA, ADPT |
| Q2 2024 | 8 | $102.8M | NTRA, GH, AKYA, CDNA, TXG |
| Q1 2024 | 8 | $106.3M | NTRA, AKYA, GH, TXG, QTRX |